Index RUT
P/E -
EPS (ttm) -1.09
Insider Own 19.30%
Shs Outstand 138.39M
Perf Week 11.08%
Market Cap 2.44B
Forward P/E -
EPS next Y -2.53
Insider Trans -0.70%
Shs Float 115.02M
Perf Month -9.74%
Income -145.22M
PEG -
EPS next Q -0.69
Inst Own 76.19%
Short Float 8.33%
Perf Quarter 6.79%
Sales 330.53M
P/S 7.39
EPS this Y -143.61%
Inst Trans -0.74%
Short Ratio 7.65
Perf Half Y -9.93%
Book/sh 7.45
P/B 2.30
EPS next Y 2.18%
ROA -11.11%
Short Interest 9.58M
Perf Year -33.72%
Cash/sh 7.26
P/C 2.36
EPS next 5Y -
ROE -14.01%
52W Range 14.56 - 33.31
Perf YTD -20.13%
Dividend Est. -
P/FCF -
EPS past 5Y -21.99%
ROI -13.50%
52W High -48.54%
Beta 1.33
Dividend TTM -
Quick Ratio 13.65
Sales past 5Y 264.19%
Gross Margin 95.49%
52W Low 17.72%
ATR (14) 0.89
Dividend Ex-Date -
Current Ratio 13.65
EPS Y/Y TTM 59.36%
Oper. Margin -59.51%
RSI (14) 48.85
Volatility 5.23% 4.62%
Employees 445
Debt/Eq 0.05
Sales Y/Y TTM 204.74%
Profit Margin -43.94%
Recom 1.24
Target Price 40.27
Option/Short Yes / Yes
LT Debt/Eq 0.04
EPS Q/Q -16.37%
Payout -
Rel Volume 0.69
Prev Close 16.81
Sales Surprise -100.00%
EPS Surprise -6.97%
Sales Q/Q -100.00%
Earnings Feb 27 BMO
Avg Volume 1.25M
Price 17.14
SMA20 0.71%
SMA50 -9.16%
SMA200 -16.13%
Trades
Volume 868,033
Change 1.96%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-13-23 Initiated
Citigroup
Buy
$32
Nov-20-23 Resumed
JP Morgan
Overweight
$28
Oct-24-23 Resumed
Cantor Fitzgerald
Overweight
$85 → $35
Sep-06-23 Initiated
B. Riley Securities
Buy
$38
Jan-30-23 Initiated
SVB Securities
Outperform
$50
Dec-05-22 Initiated
Cowen
Outperform
Nov-02-22 Upgrade
BTIG Research
Neutral → Buy
$38
Nov-02-22 Initiated
BofA Securities
Buy
$40
Jun-23-22 Initiated
Berenberg
Buy
$39
Dec-10-21 Resumed
Raymond James
Mkt Perform
Sep-21-21 Initiated
Oppenheimer
Outperform
$85
Sep-01-21 Initiated
SMBC Nikko
Outperform
$78
May-18-21 Initiated
UBS
Buy
$70
Feb-26-21 Reiterated
H.C. Wainwright
Buy
$80 → $95
Feb-10-21 Upgrade
Cantor Fitzgerald
Neutral → Overweight
$105
Nov-11-20 Reiterated
H.C. Wainwright
Buy
$65 → $80
Oct-16-20 Downgrade
BTIG Research
Buy → Neutral
Sep-14-20 Resumed
JP Morgan
Overweight
$35
Aug-20-20 Reiterated
H.C. Wainwright
Buy
$28 → $45
Mar-13-20 Upgrade
Evercore ISI
In-line → Outperform
$20
Show Previous Ratings
May-01-24 08:00AM
Apr-09-24 08:46AM
Apr-08-24 08:00AM
Mar-28-24 11:30AM
Mar-19-24 08:30AM
08:08AM
Loading…
Feb-28-24 08:08AM
Feb-27-24 08:31AM
08:05AM
08:00AM
06:53AM
Feb-16-24 08:39AM
08:22AM
07:13AM
Feb-07-24 08:00AM
Feb-01-24 08:00AM
11:04PM
Loading…
Jan-31-24 11:04PM
Jan-26-24 10:00AM
Jan-11-24 01:11PM
Jan-09-24 08:44AM
Jan-08-24 08:00AM
06:30AM
06:30AM
Jan-02-24 01:57PM
Dec-22-23 06:22AM
Dec-21-23 09:55AM
Dec-07-23 11:31AM
Nov-27-23 07:01PM
09:55AM
Nov-21-23 06:00AM
Nov-07-23 05:50PM
04:01PM
Loading…
04:01PM
Nov-06-23 09:55AM
Nov-01-23 10:30AM
Oct-19-23 10:30AM
Oct-06-23 04:41AM
Oct-02-23 07:00AM
Sep-27-23 08:31AM
Sep-11-23 06:30AM
Sep-09-23 03:59PM
Sep-07-23 11:30AM
Aug-30-23 08:30AM
Aug-29-23 09:00AM
Aug-11-23 11:36AM
Aug-10-23 12:02PM
06:03AM
Aug-08-23 06:05PM
04:01PM
Jun-29-23 05:13AM
Jun-27-23 02:23PM
Jun-26-23 10:00AM
(The Wall Street Journal)
Jun-21-23 03:21PM
06:00AM
Jun-20-23 04:20PM
07:00AM
Jun-09-23 11:30AM
Jun-08-23 11:30AM
Jun-07-23 11:30AM
Jun-05-23 06:15PM
May-31-23 01:30PM
May-16-23 06:00AM
May-15-23 04:31PM
May-09-23 01:24PM
May-08-23 05:15PM
04:01PM
May-04-23 01:21PM
May-01-23 10:00AM
Apr-27-23 10:02AM
Apr-14-23 07:03AM
Apr-12-23 08:00AM
Apr-10-23 08:00AM
Apr-04-23 05:12AM
Mar-29-23 11:30AM
Mar-04-23 07:35AM
Feb-28-23 09:01AM
Feb-27-23 05:35PM
04:01PM
Feb-23-23 11:15AM
Feb-22-23 04:33PM
Feb-21-23 10:00AM
Feb-20-23 10:00AM
Feb-15-23 04:01PM
Feb-03-23 01:22PM
Jan-25-23 08:00AM
Jan-09-23 08:00AM
Jan-02-23 06:56AM
Dec-13-22 08:15AM
Dec-06-22 06:35AM
Dec-05-22 07:00AM
Nov-09-22 05:32AM
Nov-04-22 11:52AM
06:23AM
Nov-03-22 05:55PM
04:01PM
Nov-02-22 06:11PM
Nov-01-22 08:00AM
Oct-24-22 04:30PM
Oct-19-22 09:19PM
Oct-18-22 04:40PM
Oct-10-22 07:44AM
Oct-03-22 08:00AM
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
SATO VICKI L Director Apr 15 '24 Sale 18.29 1,666 30,471 118,043 Apr 17 05:14 PM Krognes Steve E. Director Apr 01 '24 Sale 20.50 92,500 1,896,250 47,341 Apr 02 06:07 PM SATO VICKI L Director Mar 15 '24 Sale 20.10 1,666 33,487 119,709 Mar 19 04:27 PM SATO VICKI L Director Feb 15 '24 Sale 18.37 1,666 30,604 121,375 Feb 20 05:38 PM Schuth Alexander O. COFO and Secretary Feb 14 '24 Sale 17.66 20,128 355,460 187,341 Feb 15 09:14 PM Ho Carole Chief Medical Officer Feb 14 '24 Sale 17.79 1,405 24,995 143,605 Feb 15 09:14 PM Watts Ryan J. President and CEO Feb 13 '24 Sale 17.29 9,589 165,794 238,067 Feb 15 09:15 PM Ho Carole Chief Medical Officer Feb 13 '24 Sale 17.29 2,784 48,135 145,010 Feb 15 09:14 PM Krognes Steve E. Director Feb 13 '24 Sale 17.29 2,750 47,548 139,841 Feb 15 09:16 PM Schuth Alexander O. COFO and Secretary Feb 13 '24 Sale 17.29 2,716 46,960 207,469 Feb 15 09:14 PM Schuth Alexander O. COFO and Secretary Feb 08 '24 Option Exercise 0.68 50,000 34,000 210,185 Feb 12 04:48 PM SATO VICKI L Director Jan 16 '24 Sale 18.42 1,666 30,688 123,041 Jan 18 06:26 PM Ho Carole Chief Medical Officer Jan 10 '24 Sale 19.02 4,668 88,785 147,794 Jan 12 08:18 PM Watts Ryan J. President and CEO Jan 09 '24 Sale 19.78 7,818 154,640 2,268,363 Jan 11 05:28 PM Watts Ryan J. President and CEO Jan 05 '24 Sale 19.43 17,483 339,695 2,276,181 Jan 09 07:33 PM Ho Carole Chief Medical Officer Jan 05 '24 Sale 19.43 9,972 193,756 198,777 Jan 09 07:35 PM Schuth Alexander O. COFO and Secretary Jan 05 '24 Sale 19.43 9,972 193,756 539,307 Jan 09 07:34 PM Krognes Steve E. Director Jan 05 '24 Sale 19.43 3,208 62,331 142,591 Jan 09 07:34 PM SATO VICKI L Director Dec 15 '23 Sale 23.39 1,666 38,968 124,707 Dec 18 07:30 PM SATO VICKI L Director Nov 15 '23 Sale 19.13 1,666 31,871 126,373 Nov 16 06:14 PM SATO VICKI L Director Oct 16 '23 Sale 20.66 1,666 34,420 128,039 Oct 18 04:44 PM SATO VICKI L Director Sep 15 '23 Sale 23.62 1,666 39,348 129,705 Sep 19 04:45 PM Ho Carole Chief Medical Officer Aug 23 '23 Sale 23.22 2,522 58,561 182,809 Aug 25 05:30 PM Schuth Alexander O. COFO and Secretary Aug 23 '23 Sale 23.17 2,522 58,435 518,989 Aug 25 05:36 PM Ho Carole Chief Medical Officer Aug 21 '23 Sale 22.60 2,478 56,003 185,331 Aug 23 04:34 PM Schuth Alexander O. COFO and Secretary Aug 21 '23 Sale 22.59 2,478 55,978 521,511 Aug 23 04:33 PM Watts Ryan J. President and CEO Aug 21 '23 Sale 22.59 2,309 52,160 2,242,604 Aug 23 04:32 PM Krognes Steve E. Director Aug 21 '23 Sale 22.60 1,419 32,069 145,799 Aug 23 04:31 PM SATO VICKI L Director Aug 15 '23 Sale 24.30 1,666 40,484 131,371 Aug 17 06:42 PM Ho Carole Chief Medical Officer Aug 14 '23 Sale 23.79 2,768 65,851 182,809 Aug 16 06:20 PM Schuth Alexander O. COFO and Secretary Aug 14 '23 Sale 23.67 2,772 65,613 518,989 Aug 16 06:19 PM Watts Ryan J. President and CEO Aug 10 '23 Option Exercise 0.68 2,526 1,718 2,242,439 Aug 14 05:13 PM Ho Carole Chief Medical Officer Aug 10 '23 Sale 24.15 2,857 68,997 185,577 Aug 14 05:12 PM Schuth Alexander O. COFO and Secretary Aug 10 '23 Sale 24.18 2,853 68,986 521,761 Aug 14 05:11 PM Watts Ryan J. President and CEO Aug 10 '23 Sale 25.03 2,526 63,226 2,239,913 Aug 14 05:13 PM Schuth Alexander O. COFO and Secretary Jul 18 '23 Sale 30.01 9,702 291,157 518,989 Jul 19 05:10 PM Schuth Alexander O. COFO and Secretary Jul 17 '23 Option Exercise 5.28 10,000 52,800 538,691 Jul 19 05:10 PM Schuth Alexander O. COFO and Secretary Jul 17 '23 Sale 29.60 10,000 296,000 528,691 Jul 19 05:10 PM SATO VICKI L Director Jul 17 '23 Sale 29.60 1,666 49,314 133,037 Jul 19 05:09 PM SATO VICKI L Director Jun 28 '23 Sale 29.84 1,666 49,709 134,703 Jun 30 05:21 PM Schuth Alexander O. COFO and Secretary May 15 '23 Option Exercise 5.28 10,000 52,800 538,691 May 17 04:56 PM Schuth Alexander O. COFO and Secretary May 15 '23 Sale 28.60 10,000 286,044 528,691 May 17 04:56 PM
Index NDX, S&P 500
P/E 28.27
EPS (ttm) 33.85
Insider Own 4.23%
Shs Outstand 107.60M
Perf Week 8.36%
Market Cap 105.43B
Forward P/E 20.19
EPS next Y 47.39
Insider Trans -2.12%
Shs Float 105.52M
Perf Month 2.13%
Income 3.86B
PEG 2.86
EPS next Q 10.58
Inst Own 84.42%
Short Float 1.31%
Perf Quarter 1.25%
Sales 13.10B
P/S 8.05
EPS this Y 0.86%
Inst Trans -0.34%
Short Ratio 2.93
Perf Half Y 20.94%
Book/sh 244.93
P/B 3.91
EPS next Y 7.31%
ROA 11.98%
Short Interest 1.39M
Perf Year 19.15%
Cash/sh 95.48
P/C 10.02
EPS next 5Y 9.90%
ROE 15.28%
52W Range 684.80 - 998.33
Perf YTD 8.96%
Dividend Est. -
P/FCF 25.94
EPS past 5Y 10.31%
ROI 12.99%
52W High -4.14%
Beta 0.11
Dividend TTM -
Quick Ratio 4.51
Sales past 5Y 19.99%
Gross Margin 83.00%
52W Low 39.75%
ATR (14) 21.10
Dividend Ex-Date -
Current Ratio 5.27
EPS Y/Y TTM -7.49%
Oper. Margin 30.81%
RSI (14) 64.09
Volatility 3.00% 2.10%
Employees 13450
Debt/Eq 0.10
Sales Y/Y TTM 5.90%
Profit Margin 29.45%
Recom 1.83
Target Price 1052.09
Option/Short Yes / Yes
LT Debt/Eq 0.10
EPS Q/Q -12.56%
Payout 0.00%
Rel Volume 1.11
Prev Close 937.61
Sales Surprise -2.49%
EPS Surprise -6.11%
Sales Q/Q -0.54%
Earnings May 02 BMO
Avg Volume 472.87K
Price 957.00
SMA20 5.26%
SMA50 1.35%
SMA200 10.30%
Trades
Volume 525,987
Change 2.07%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-12-24 Initiated
Bernstein
Outperform
$1125
Jan-12-24 Upgrade
RBC Capital Mkts
Sector Perform → Outperform
$884 → $1076
Nov-09-23 Initiated
Deutsche Bank
Hold
$800
Nov-03-23 Upgrade
Raymond James
Mkt Perform → Outperform
$950
Aug-21-23 Upgrade
Canaccord Genuity
Hold → Buy
$720 → $992
Aug-21-23 Reiterated
Oppenheimer
Perform
$950 → $1050
Jun-28-23 Downgrade
Canaccord Genuity
Buy → Hold
$953 → $720
Mar-27-23 Upgrade
SVB Securities
Market Perform → Outperform
$834 → $976
Mar-24-23 Upgrade
Jefferies
Hold → Buy
$675 → $925
Mar-23-23 Upgrade
Raymond James
Underperform → Mkt Perform
Jan-30-23 Upgrade
Cowen
Market Perform → Outperform
$775 → $875
Jan-20-23 Upgrade
JP Morgan
Neutral → Overweight
$850
Oct-26-22 Downgrade
Raymond James
Mkt Perform → Underperform
Oct-17-22 Downgrade
Evercore ISI
Outperform → In-line
$760
Sep-09-22 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$625 → $851
Sep-09-22 Upgrade
Jefferies
Underperform → Hold
$536 → $675
Jul-25-22 Downgrade
SVB Leerink
Outperform → Mkt Perform
$630
Jul-13-22 Initiated
Cantor Fitzgerald
Neutral
$625
Jun-06-22 Initiated
Jefferies
Underperform
$536
May-23-22 Initiated
SVB Leerink
Outperform
$738
Show Previous Ratings
May-04-24 12:00PM
07:38AM
May-03-24 10:20AM
10:15AM
09:56AM
06:15AM
Loading…
06:15AM
03:10AM
01:08AM
May-02-24 04:03PM
(Investor's Business Daily)
02:51PM
01:54PM
01:52PM
10:53AM
10:01AM
09:30AM
08:32AM
Loading…
08:32AM
07:15AM
07:09AM
06:45AM
(Investor's Business Daily)
06:44AM
06:44AM
(Associated Press Finance)
06:39AM
06:34AM
06:30AM
May-01-24 06:42AM
(Pharmaceutical Technology)
Apr-30-24 08:47AM
Apr-29-24 09:35AM
09:16AM
07:00AM
Apr-28-24 06:32PM
12:24PM
Loading…
Apr-26-24 12:24PM
08:24AM
Apr-25-24 11:42AM
(The Wall Street Journal)
10:02AM
08:44AM
08:15AM
07:00AM
07:00AM
03:00AM
Apr-24-24 10:05AM
Apr-22-24 05:54PM
Apr-16-24 12:10PM
Apr-15-24 07:59PM
07:24PM
07:20PM
07:45AM
04:46AM
Apr-12-24 01:54PM
Apr-11-24 04:43PM
02:02PM
(Investor's Business Daily)
01:59PM
(The Wall Street Journal)
01:07PM
01:01PM
(Investor's Business Daily)
12:45PM
(Investor's Business Daily)
08:17AM
07:34AM
07:06AM
Apr-10-24 04:59PM
04:52PM
04:31PM
Apr-09-24 07:37AM
Apr-07-24 04:00PM
Apr-05-24 07:00AM
Apr-03-24 10:03PM
Apr-01-24 04:05PM
Mar-28-24 08:00AM
01:00AM
Mar-26-24 10:37AM
06:44AM
Mar-25-24 07:55AM
07:27AM
07:07AM
07:00AM
Mar-18-24 01:28PM
Mar-17-24 05:20PM
Mar-13-24 10:55AM
Mar-12-24 11:55PM
12:32PM
Mar-11-24 07:00AM
Mar-09-24 05:52AM
Mar-08-24 08:15AM
07:00AM
Mar-05-24 07:31AM
Mar-04-24 04:09PM
Feb-23-24 10:20AM
(Investor's Business Daily)
01:00AM
01:00AM
Feb-22-24 01:55PM
Feb-21-24 10:00AM
07:00AM
Feb-18-24 12:45AM
Feb-16-24 01:00AM
12:59AM
Feb-10-24 08:30AM
Feb-09-24 06:45AM
Feb-06-24 04:05PM
06:45AM
Feb-05-24 07:00AM
(The Wall Street Journal)
Feb-03-24 08:10AM
01:53AM
(Thomson Reuters StreetEvents)
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
McCourt Marion EVP Commercial May 01 '24 Sale 889.41 250 222,352 12,931 May 03 04:02 PM RYAN ARTHUR F Director May 01 '24 Sale 899.61 100 89,961 18,082 May 03 04:01 PM McCourt Marion EVP Commercial Apr 01 '24 Sale 964.73 250 241,182 13,181 Apr 03 04:05 PM RYAN ARTHUR F Director Apr 01 '24 Sale 962.53 100 96,253 18,182 Apr 03 04:06 PM MURPHY ANDREW J EVP Research Mar 14 '24 Sale 956.47 5,783 5,531,290 48,306 Mar 15 04:01 PM MURPHY ANDREW J EVP Research Mar 13 '24 Option Exercise 399.66 20,000 7,993,200 68,306 Mar 15 04:01 PM McCourt Marion EVP Commercial Mar 01 '24 Sale 967.50 358 346,365 13,431 Mar 05 04:01 PM RYAN ARTHUR F Director Mar 01 '24 Sale 982.05 100 98,205 18,282 Mar 05 04:01 PM SING GEORGE L Director Feb 26 '24 Option Exercise 413.33 1,000 413,330 26,849 Feb 28 04:04 PM Bassler Bonnie L Director Feb 26 '24 Option Exercise 391.92 854 334,700 2,236 Feb 26 04:07 PM SING GEORGE L Director Feb 26 '24 Sale 992.50 1,000 992,500 26,349 Feb 28 04:04 PM LAROSA JOSEPH J EVP General Counsel and Secret Feb 26 '24 Sale 990.00 1,000 990,000 36,543 Feb 28 04:04 PM Bassler Bonnie L Director Feb 26 '24 Sale 979.25 854 836,280 1,382 Feb 26 04:07 PM SING GEORGE L Director Feb 23 '24 Option Exercise 413.33 500 206,665 26,849 Feb 26 04:07 PM SING GEORGE L Director Feb 23 '24 Sale 985.00 500 492,500 26,349 Feb 26 04:07 PM SING GEORGE L Director Feb 22 '24 Option Exercise 413.33 3,000 1,239,990 27,349 Feb 26 04:07 PM SING GEORGE L Director Feb 22 '24 Sale 965.00 3,000 2,895,000 26,349 Feb 26 04:07 PM LAROSA JOSEPH J EVP General Counsel and Secret Feb 22 '24 Sale 967.65 1,000 967,650 37,543 Feb 26 04:07 PM YANCOPOULOS GEORGE Bd. Co-Chair, President & CSO Feb 15 '24 Option Exercise 399.66 172,723 69,030,474 925,209 Feb 20 04:03 PM Van Plew Daniel P EVP & General Mgr, Industrial Feb 14 '24 Sale 942.28 10,434 9,831,727 20,378 Feb 16 04:15 PM Van Plew Daniel P EVP & General Mgr, Industrial Feb 09 '24 Option Exercise 378.30 35,375 13,382,510 47,153 Feb 13 04:04 PM SING GEORGE L Director Feb 09 '24 Option Exercise 413.33 500 206,665 26,849 Feb 12 04:02 PM Fenimore Christopher R. SVP Finance & CFO Feb 09 '24 Sale 953.31 4,919 4,689,320 14,372 Feb 12 04:02 PM SING GEORGE L Director Feb 09 '24 Sale 955.00 500 477,500 26,349 Feb 12 04:02 PM SING GEORGE L Director Feb 08 '24 Option Exercise 413.33 500 206,665 26,849 Feb 12 04:02 PM SING GEORGE L Director Feb 08 '24 Sale 945.00 500 472,500 26,349 Feb 12 04:02 PM STAHL NEIL EVP Research and Development Feb 07 '24 Sale 950.35 8,037 7,637,954 52,019 Feb 08 04:02 PM LAROSA JOSEPH J EVP General Counsel and Secret Feb 07 '24 Sale 950.00 1,000 950,000 38,543 Feb 09 04:12 PM McCourt Marion EVP Commercial Feb 05 '24 Sale 934.71 1,000 934,710 13,789 Feb 06 04:08 PM STAHL NEIL EVP Research and Development Feb 02 '24 Option Exercise 399.66 30,750 12,289,545 82,769 Feb 06 04:08 PM Landry Robert E EVP Finance CFO Feb 02 '24 Option Exercise 378.98 400 151,592 23,974 Feb 06 04:08 PM McCourt Marion EVP Commercial Feb 01 '24 Sale 945.61 273 258,152 14,789 Feb 02 04:02 PM RYAN ARTHUR F Director Feb 01 '24 Sale 954.22 100 95,422 18,382 Feb 05 04:05 PM Landry Robert E EVP Finance CFO Jan 31 '24 Option Exercise 378.98 400 151,592 23,856 Feb 02 04:02 PM Bassler Bonnie L Director Jan 30 '24 Option Exercise 380.95 827 315,046 2,209 Jan 31 04:52 PM Bassler Bonnie L Director Jan 30 '24 Sale 959.00 827 793,093 1,382 Jan 31 04:52 PM Landry Robert E EVP Finance CFO Jan 24 '24 Option Exercise 378.98 500 189,490 23,808 Jan 25 04:17 PM Fenimore Christopher R. SVP Controller Jan 23 '24 Option Exercise 477.67 10,000 4,776,650 22,874 Jan 25 04:17 PM GOLDSTEIN JOSEPH L Director Jan 23 '24 Option Exercise 625.60 2,707 1,693,499 9,089 Jan 25 04:18 PM Landry Robert E EVP Finance CFO Jan 23 '24 Option Exercise 378.98 1,100 416,878 24,084 Jan 25 04:17 PM GOLDSTEIN JOSEPH L Director Jan 23 '24 Sale 950.00 2,707 2,571,650 6,382 Jan 25 04:18 PM Landry Robert E EVP Finance CFO Jan 17 '24 Option Exercise 378.98 500 189,490 23,338 Jan 18 04:02 PM Landry Robert E EVP Finance CFO Jan 12 '24 Option Exercise 378.98 800 303,184 23,406 Jan 17 04:03 PM Landry Robert E EVP Finance CFO Jan 04 '24 Option Exercise 378.98 500 189,490 22,948 Jan 08 04:02 PM LAROSA JOSEPH J EVP General Counsel and Secret Jan 03 '24 Option Exercise 399.66 34,000 13,588,440 64,036 Jan 04 04:19 PM Fenimore Christopher R. SVP Controller Jan 03 '24 Option Exercise 477.67 10,000 4,776,650 20,329 Jan 04 04:22 PM Landry Robert E EVP Finance CFO Jan 03 '24 Option Exercise 378.98 1,100 416,878 23,136 Jan 04 04:19 PM Bassler Bonnie L Director Jan 03 '24 Option Exercise 380.95 826 314,665 2,208 Jan 04 04:11 PM Bassler Bonnie L Director Jan 03 '24 Sale 914.00 826 754,964 1,382 Jan 04 04:11 PM Zoghbi Huda Y Director Jan 02 '24 Option Exercise 391.92 1,117 437,775 2,364 Jan 04 04:11 PM Landry Robert E EVP Finance CFO Jan 02 '24 Option Exercise 378.98 650 246,337 22,457 Jan 04 04:19 PM YANCOPOULOS GEORGE Bd. Co-Chair, President & CSO Jan 02 '24 Sale 900.00 16,848 15,163,200 180,000 May 01 04:00 PM YANCOPOULOS GEORGE Bd. Co-Chair, President & CSO Jan 02 '24 Sale 900.00 16,848 15,163,200 180,000 Jan 04 04:20 PM Zoghbi Huda Y Director Jan 02 '24 Sale 900.00 1,117 1,005,300 1,247 Jan 04 04:11 PM McCourt Marion EVP Commercial Jan 02 '24 Sale 873.91 274 239,451 15,062 Jan 04 04:17 PM RYAN ARTHUR F Director Jan 02 '24 Sale 899.90 100 89,990 18,347 Jan 04 04:08 PM Landry Robert E EVP Finance CFO Dec 28 '23 Option Exercise 378.98 850 322,133 22,419 Dec 29 04:05 PM BROWN MICHAEL S Director Dec 27 '23 Option Exercise 482.68 2,049 989,011 3,296 Dec 29 04:06 PM Landry Robert E EVP Finance CFO Dec 27 '23 Option Exercise 378.98 750 284,235 22,111 Dec 29 04:05 PM Fenimore Christopher R. SVP Controller Dec 27 '23 Sale 856.71 2,448 2,097,226 14,372 Dec 29 04:04 PM BROWN MICHAEL S Director Dec 27 '23 Sale 898.00 2,049 1,840,002 1,247 Dec 29 04:06 PM Fenimore Christopher R. SVP Controller Dec 22 '23 Sale 846.27 250 211,568 16,820 Dec 26 04:08 PM Fenimore Christopher R. SVP Controller Dec 21 '23 Sale 844.01 1,680 1,417,934 17,070 Dec 26 04:08 PM Landry Robert E EVP Finance CFO Dec 13 '23 Option Exercise 378.98 1,000 378,980 22,084 Dec 14 04:08 PM Bassler Bonnie L Director Dec 13 '23 Option Exercise 376.69 610 229,781 1,857 Dec 14 04:07 PM Bassler Bonnie L Director Dec 13 '23 Sale 870.00 610 530,700 1,247 Dec 14 04:07 PM McCourt Marion EVP Commercial Dec 11 '23 Sale 838.44 270 226,379 20,814 Dec 12 04:04 PM MURPHY ANDREW J EVP Research Dec 05 '23 Sale 817.44 6,536 5,342,787 59,421 Dec 06 04:02 PM MURPHY ANDREW J EVP Research Dec 04 '23 Option Exercise 270.43 20,000 5,408,600 79,421 Dec 06 04:02 PM RYAN ARTHUR F Director Dec 01 '23 Sale 817.30 100 81,730 18,447 Dec 04 04:02 PM MURPHY ANDREW J EVP Research Nov 14 '23 Sale 799.17 6,492 5,188,213 59,421 Nov 15 04:02 PM MURPHY ANDREW J EVP Research Nov 13 '23 Option Exercise 270.43 20,000 5,408,600 79,421 Nov 15 04:02 PM RYAN ARTHUR F Director Nov 07 '23 Sale 827.90 100 82,790 18,547 Nov 08 04:07 PM McCourt Marion EVP Commercial Nov 01 '23 Option Exercise 381.40 1,000 381,400 20,803 Nov 02 04:03 PM McCourt Marion EVP Commercial Nov 01 '23 Sale 783.91 1,000 783,910 19,803 Nov 02 04:03 PM Zoghbi Huda Y Director Oct 13 '23 Option Exercise 391.92 1,000 391,920 2,247 Oct 17 04:06 PM Zoghbi Huda Y Director Oct 13 '23 Sale 850.00 1,000 850,000 1,247 Oct 17 04:06 PM McCourt Marion EVP Commercial Oct 02 '23 Option Exercise 372.46 1,038 386,613 20,841 Oct 03 04:04 PM McCourt Marion EVP Commercial Oct 02 '23 Sale 827.00 1,038 858,426 19,803 Oct 03 04:04 PM McCourt Marion EVP Commercial Sep 01 '23 Sale 834.55 250 208,638 19,803 Sep 06 04:03 PM Van Plew Daniel P EVP & General Mgr, Industrial Aug 24 '23 Sale 841.71 6,197 5,216,073 21,508 Aug 25 04:02 PM Van Plew Daniel P EVP & General Mgr, Industrial Aug 23 '23 Option Exercise 381.40 23,125 8,819,875 44,633 Aug 25 04:02 PM POON CHRISTINE A Director Aug 23 '23 Option Exercise 273.67 12,280 3,360,668 14,317 Aug 25 04:02 PM Fenimore Christopher R. SVP Controller Aug 23 '23 Option Exercise 399.66 7,000 2,797,620 26,140 Aug 25 04:03 PM POON CHRISTINE A Director Aug 23 '23 Sale 839.97 12,280 10,314,829 2,037 Aug 25 04:02 PM Landry Robert E EVP Finance CFO Aug 23 '23 Sale 844.00 223 188,212 31,699 Aug 25 04:02 PM STAHL NEIL EVP Research and Development Aug 22 '23 Sale 840.98 11,665 9,810,082 53,100 Aug 23 04:03 PM STAHL NEIL EVP Research and Development Aug 21 '23 Option Exercise 399.66 50,000 19,983,000 103,100 Aug 23 04:03 PM Bassler Bonnie L Director Aug 21 '23 Option Exercise 391.92 853 334,308 2,100 Aug 23 04:03 PM Bassler Bonnie L Director Aug 21 '23 Sale 829.00 853 707,137 1,247 Aug 23 04:03 PM Bassler Bonnie L Director Aug 10 '23 Option Exercise 391.92 853 334,308 2,100 Aug 11 04:13 PM Bassler Bonnie L Director Aug 10 '23 Sale 789.00 853 673,017 1,247 Aug 11 04:13 PM McCourt Marion EVP Commercial Aug 01 '23 Sale 744.66 250 186,165 20,053 Aug 03 04:02 PM RYAN ARTHUR F Director Aug 01 '23 Sale 736.59 100 73,659 18,647 Aug 03 04:25 PM McCourt Marion EVP Commercial Jul 03 '23 Sale 710.09 250 177,522 20,303 Jul 06 04:02 PM RYAN ARTHUR F Director Jul 03 '23 Sale 716.88 100 71,688 18,747 Jul 06 04:01 PM McCourt Marion EVP Commercial Jun 01 '23 Sale 736.00 250 184,000 20,553 Jun 02 04:12 PM RYAN ARTHUR F Director Jun 01 '23 Sale 735.42 100 73,542 18,847 Jun 02 04:14 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite